Enveric Biosciences receives notice of allowance from USPTO for its drug candidate EB-003 to treat mental health disorders: Cambridge, Massachusetts Saturday, February 1, 2025, 13 ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

It’s an hallucinogenic tryptamine drug and produces a psychedelic experience similar to that of LSD and magic mushrooms. There are many serious medical side effects including mental issues that ...

Tryptamine Therapeutics Ltd (ASX ... “It further validates Tryp’s approach to drug development and also serves as a ...

Tryptamine is focused on the development of an IV-infused psilocin solution which can be used with therapy to address unmet medical needs. The company said its lead asset TRP-8803 aimed to ...

Neuren’s partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment of Rett syndrome Compumedics achieves a record $32.8m in sales orders in H1 ...